GlassScriptPhysician profile
Samuel Wan Park
NPI 1710181854
$79,245.00
in general payments reported to CMS, 2019-2025
35 companies · $21K in 2025
The $21K reported for 2025 was more than what 91% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $17K · 2021: $12K · 2022: $4,043 · 2023: $4,566 · 2024: $6,786 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $16K · Consulting Fee: $12K · Travel and Lodging: $2,697 · Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15,825.34 |
| Consulting Fee | $11,975.00 |
| Travel and Lodging | $2,697.17 |
| Food and Beverage | $2,284.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $75,842.42 | 2019-2025 | Rosa, G7, Persona |
| Stryker Corporation | $1,979.11 | 2019-2025 | Hoffmann, Gamma, Pangea |
| Globus Medical, INC. | $144.50 | 2022-2024 | Mini Fragment System, Distal Femur Plate System, Evo Retrograde |
| Horizon Therapeutics Plc | $96.67 | 2019-2022 | |
| Medical Device Business Services, INC. | $79.91 | 2023 | Attune |
| Medline Industries LP | $76.23 | 2019-2021 | |
| Linvatec Corporation | $71.04 | 2021-2023 | Biobrace 23mm |
| Smith+Nephew, INC. | $68.92 | 2019-2023 | Renasys Go V2 Home |
| Medtronic, INC. | $68.16 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Heraeus Medical, LLC. | $62.96 | 2022-2023 | Palacos |
| Depuy Synthes Sales INC. | $61.37 | 2020-2021 | |
| Bioventus LLC | $60.61 | 2020-2023 | Supartz Fx Sodium Hyaluronate |
| Integra Lifesciences Corporation | $56.34 | 2020-2021 | |
| Breg, INC | $50.34 | 2025 | |
| Endo Pharmaceuticals INC. | $46.53 | 2019-2023 | Xiaflex |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bsn Medical INC | $45.72 | 2019 | |
| Molnlycke Health Care US, LLC | $44.06 | 2024 | Avance, Mepilex Ag, Mepilex Border Ag |
| Aroa Biosurgery Incorporated | $35.89 | 2022 | |
| Ethicon US, LLC | $31.41 | 2022 | |
| Biotissue Holdings INC. | $29.83 | 2023 | |
| Ferring Pharmaceuticals INC. | $27.88 | 2019 | |
| Ermi LLC | $25.34 | 2019 | |
| Inari Medical, INC. | $23.92 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Heron Therapeutics, INC. | $21.66 | 2021 | |
| Convatec INC. | $21.41 | 2019 | |
| Saxum Surgical, INC. | $21.21 | 2025 | |
| Avanos Medical | $20.63 | 2023 | Trivisc Sodium Hyaluronate |
| Acumed LLC | $20.12 | 2022 | |
| Guard Medical INC. | $19.84 | 2024 | Npseal Large |
| Fidia Pharma USA INC. | $17.90 | 2022 | |
| Davol INC. | $17.53 | 2024 | Arista Ah Flexitip |
| Nevro Corp. | $16.11 | 2019 | |
| Medartis INC. | $14.64 | 2020 | |
| Baudax Bio INC. | $13.48 | 2020 | |
| Arthrosurface Incorporated | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.